InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,471.04
(
-0.04%
)
US TECH 100
19,224.00
(
-0.18%
)
Dow Jones
39,178.24
(
0.11%
)
Brent Oil
85.26
(
0.29%
)
Bitcoin
64,250.00
(
-0.88%
)
Post# of 252283
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: DewDiligence post# 217669

Sunday, 03/04/2018 8:32:07 PM

Sunday, March 04, 2018 8:32:07 PM

Post# of 252283
RCC / epacadostat:

I don't think the currently running phase 3 in RCC will meet its primary PFS endpoint. And even if it does, I don't think the data will be clinically competitive. They're running against sunitinib / pazopanib but I think newer drugs like axitinib are the real competition. Axitinib has also had some very strong response rate data in the 80% range in combination with PD-1 inhibitors.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up